Market Overview

Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on May 9)

  • Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) (reported Q1 results before the market open on Wednesday)
  • AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)
  • Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) (reported Q2 results after the close on Tuesday)
  • BioLife Solutions Inc (NASDAQ: BLFS)
  • Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) (reported Q1 results after the market close on Tuesday)
  • BioTelemetry Inc (NASDAQ: BEAT)
  • CareDx Inc (NASDAQ: CDNA) ( announced a licensing and commercialization agreement with Illumina, Inc. (NASDAQ: ILMN), which gave the former rights to latter's next-gen sequencing product line for use in transplantation diagnostic testing)
  • Cerus Corporation (NASDAQ: CERS) (reported Q1 results after the close on Tuesday)
  • Eloxx Pharmaceuticals Inc (NASDAQ: ELOX)
  • Haemonetics Corporation (NYSE: HAE)
  • Inogen Inc (NASDAQ: INGN)
  • Irhythm Technologies Inc (NASDAQ: IRTC)
  • Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
  • Novocure Ltd (NASDAQ: NVCR)
  • Penumbra Inc (NYSE: PEN)(reported Q1 results after the close on Tuesday)
  • Regenxbio Inc (NASDAQ: RGNX)(reported Q1 results after the close on Tuesday)
  • Tactile Systems Technology Inc (NASDAQ: TCMD)

Down In The Dumps

(Stocks hitting 52-week lows on May 9)

  • Aralez Pharmaceuticals Inc (NASDAQ: ARLZ)
  • BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
  • Lipocine Inc (NASDAQ: LPCN)(FDA issued a complete response letter to the NDA for its testosterone replacement therapy)
  • RXi Pharmaceuticals Corp (NASDAQ: RXII)
  • Sanofi SA (ADR) (NYSE: SNY)

Stocks In Focus

ARMO-Eli Lilly

ARMO Biosciences Inc (NASDAQ: ARMO) announced a deal to be bought by Eli Lilly And Co (NYSE: LLY) for $50 per share or $1.6 billion in total in an all-cash deal.

The stock was skyrocketing 67.57 percent to $49.97 in Thursday's pre-market trading.

Exelixis' Late-Stage Study of Colorectal Cancer Combo Drug Fails

Exelixis, Inc. (NASDAQ: EXEL) announced that a Phase 3 pivotal trial dubbed IMblaze370 that tested cotellic, its MEK inhibitor, and Roche's Genentech unit's tencentriq did not meet the primary endpoint of improving overall survival versus regorafenib. The combo drug was evaluated for use by patients with difficult-to-treat, locally advanced or metastatic colorectal cancer, whose disease had progressed or who were intolerant to at least two systemic chemotherapy regimens.

Integra Lifesciences Pulls Back On Pricing Of Common Stock Offering

Integra Lifesciences Holdings Corp (NASDAQ: IART) announced it has priced its offering of 5.25 million shares at $58.50 per share.

The stock fell 4.45 percent to $61 in after-hours trading Wednesday.

Sellas Gains On Orphan Drug Status

Sellas Life Sciences Group Inc (NASDAQ: SLS) said the FDA has granted orphan drug designation to its galinpepimut-S for treating multiple myeloma. The designation is given to develop therapies for rare diseases or disorders affecting fewer than 200,000 in the U.S. It vests the company some advantages, such as a 7-year market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees.

The stock added 2.34 percent to $5.69 after hours Wednesday.

vTv Therapeutics' Alzheimer's Therapy Found Effective In Subpopulation

vTv Therapeutics Inc (NASDAQ: VTVT) said post-hoc analyses of data from Part A of it Phase 3 STEADFAST study that evaluated its Alzheimer's therapy azeliragon threw up a subpopulation that showed statistically significant benefit relative to placebo.

The subpopulation consisted of participants with peak azeliragon blood plasma concentration of less than 7.5 ng/ml.

Based on this, the company said it will submit to the FDA a revised study plan for the Part B study.

Topline efficacy results from the Part B study based on 12-month data is due in June.

The stock jumped 20.47 percent to $2.06 after hours.

Catalyst Pharma Posts In-line Loss

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) reported a Q1 non-GAAP loss of 6 cents per share, in line with estimates.

The stock jumped 17.86 percent to $3.30 in after-hours trading.

Wright Medical Loss Narrows

Wright Medical Group NV (NASDAQ: WMGI) reported a narrower Q1 loss of 1 cent per share and revenues of $198.54 million, ahead of the consensus estimates. The company reiterated its FY18 guidance.

The stock gained 8.44 percent to $22.75 after hours.

Inovio Q1 Misses Estimate

Inovio Pharmaceuticals (NASDAQ: INO) reported a Q1 loss of 36 cents per share, wider than the 14 cents per share loss estimated by analysts.

Inovio slid 6.83 percent to $4.50 after hours trading.

See Also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Adverum'a Q1 Revenues Light

Adverum Biotechnologies Inc (NASDAQ: ADVM) reported a narrower-than-expected Q1 loss, while its revenues were slightly below estimates.

The stock shed 5.90 percent to $5.50.

Mannkind Disappoints With Q1 Results

MannKind Corporation (NASDAQ: MNKD) reported a wider-than-expected Q1 loss and below-consensus revenues. MannKind stock declined 5.03 percent to $1.70.

PDL Biopharma Q1 Trails Estimates

PDL BioPharma Inc (NASDAQ: PDLI) announced Q1 results, showing a profit of 1 cent per share compared to 6 cents per share expected by analysts. Revenues of $38.52 million also missed the consensus estimate of $50.4 million.

The stock receded 6.45 percent to $2.90 in after-hours trading.

Cara's Q1 Miss

Cara Therapeutics Inc (NASDAQ: CARA) reported below-consensus Q1 results.

Cara fell 6.42 percent to $12.10 in after-hours trading.

Other Stocks That Reacted to Earnings

(Thursday after-hours quote)

Portola Pharmaceuticals Inc (NASDAQ: PTLA) – Up 2.41 percent to $43.30
Novavax, Inc. (NASDAQ: NVAX) – Down 2.92 percent to $1.66
Puma Biotechnology Inc (NASDAQ: PBYI) – Down 1.99 percent to $64
Savara Inc (NASDAQ: SVRA) – Down 1.94 percent to $9.60
Immunomedics, Inc. (NASDAQ: IMMU) – Down 3.55 percent to $18.20

On The Radar

The following companies are scheduled to report earnings on Thursday:

  • Depomed Inc (NASDAQ: DEPO)
  • Fate Therapeutics Inc (NASDAQ: FATE)
  • Karyopharm Therapeutics Inc (NASDAQ: KPTI)
  • Nektar Therapeutics (NASDAQ: NKTR)
  • Athersys, Inc. (NASDAQ: ATHX)
  • BioDelivery Sciences International, Inc (NASDAQ: BDSI)
  • Eagle Pharmaceuticals Inc (NASDAQ: EGRX)
  • BioTime, Inc. (NYSE: BTX)
  • CareDx Inc (NASDAQ: CDNA)
  • Halozyme Therapeutics, Inc. (NASDAQ: HALO)
  • Strongbridge Biopharma plc (NASDAQ: SBBP)
  • Synergy Pharmaceuticals Inc (NASDAQ: SGYP)
  • Catabasis Pharmaceuticals Inc (NASDAQ: CATB)
  • RXi Pharmaceuticals Corp (NASDAQ: RXII)
  • Catalyst Pharmaceuticals Inc (NASDAQ: CPRX)
  • Fibrocell Science Inc (NASDAQ: FCSC)

Adcom Meeting Schedule

The Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet to discuss the safety and efficacy of Akcea Therapeutics Inc (NASDAQ: AKCA) subcutaneously injected volanesoren solution for patients with familial chylomicronemia syndrome.

FDA Tidbits

The FDA filed with the federal court, seeking permanent injunctions against two stem cell clinics for deviating from current good manufacturing practice requirements. These clinics are also prohibited from marketing stem cell products without the agency's approval.


Related Articles (IBB + VTVT)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Guidance FDA Top Stories Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at